• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

FDA starts speedy review of Keytruda for adjuvant kidney cancer

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 11, 2021 at 11:12: AM
via Merck & Co is looking at a decision from the FDA in December on its application to market Keytruda as a post-surgery treatment for people with kidney cancer, after a priority review.

article source
 




Top Bottom
Back
Quote